Live feed
·
NEWSReleasevia Quantisnow
Actuate Therapeutics Inc. logo

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

ByQuantisnow·Wall Street's wire, on your screen.
ACTU· Actuate Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACTU (Actuate Therapeutics Inc.) and more on Quantisnow.